Abstract
The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have